Loading, please wait....jpg)
.jpg)
The Premier June 17, 2025 CE webinar will be held from 12 - 1 pm EDT. We are pleased to provide one (1) 60-minute knowledge-based, ACPE-accredited CE activity to pharmacists and pharmacy technicians.
Incorporating Anti-Amyloid-β (Aβ) Monoclonal Antibody Therapies into Alzheimer’s Disease Management
SPEAKER: Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP, Dean and Professor, Pacific University School of Pharmacy, Hillboro, OR
ACPE Universal Activity Number: 0122-0000-25-012-L01-T [0.1 CEU] [1 Contact Hr.]
Date: Jun 17, 2025 12:00 PM - 01:00 PM
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Registration closes on Jun 17, 2025 12:10 PM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacy Technicians
Accreditation(s)
|
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
CE participation will be provided to CPE Monitor within 45 days of the CE activity upon CE registration, confirmation of participation for the entire activity, and completion of online learning assessment questions and speaker evaluation administered post-session.
Support/Credits
Premier, Inc. has received no outside support for the administration of this program.
Registration closes on Jun 17, 2025
at 12:10 PM
Registration closes on Jun 17, 2025
at 12:10 PM
Registration Closed
Registration Closed
Objectives
- Discuss currently available pharmacologic treatments for Alzheimer’s disease
- Describe the benefits of the current available treatments for Alzheimer's Disease, including anti-amyloid-B monoclonal antibodies
- Identify the type of patient that may be eligible to receive anti-amyloid-B monoclonal antibody treatment options
- List common adverse effects of anti-amyloid-B monoclonal antibodies for Alzheimer's disease
Speaker(s)/Author(s)
|
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP
|
Activity Number
0122-0000-25-012-L01-T
Date:
06/17/25
Time:
12:00 PM - 01:00 PM
CE Hours
1.00
Registration Closed